A Phase 3 Prospective, Randomized, Multicenter, Open Label, Central Assessor Blinded, Parallel Group, Comparative Study To Determine The Efficacy, Safety And Tolerability Of Aztreonam Avibactam (Atm Avi) ±Metronidazole (Mtz) Versus Meropenem±Colistin (Mer±Col) For The Treatment Of Serious Infections Due To Gram Negative Bacteria, Including Metallo Β Lactamase (Mbl) - Producing Multidrug Resistant Pathogens, For Which There Are Limited Or No Treatment Options

Trial Profile

A Phase 3 Prospective, Randomized, Multicenter, Open Label, Central Assessor Blinded, Parallel Group, Comparative Study To Determine The Efficacy, Safety And Tolerability Of Aztreonam Avibactam (Atm Avi) ±Metronidazole (Mtz) Versus Meropenem±Colistin (Mer±Col) For The Treatment Of Serious Infections Due To Gram Negative Bacteria, Including Metallo Β Lactamase (Mbl) - Producing Multidrug Resistant Pathogens, For Which There Are Limited Or No Treatment Options

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs Avibactam/aztreonam (Primary) ; Colistin; Meropenem; Metronidazole
  • Indications Intra-abdominal infections
  • Focus Registrational; Therapeutic Use
  • Acronyms REVISIT
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top